Drug intelligence / Profile preview

travoprost + timolol

Development stage
Phase 4
Lead developer
Alcon
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Travoprost + timolol is a fixed-dose combination ophthalmic solution containing two active substances: travoprost, a prostaglandin F2α analogue, and timolol, a non-selective beta adrenergic receptor antagonist. Travoprost lowers intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways through full agonism at the prostaglandin FP receptor. Timolol reduces intraocular pressure by decreasing aqueous humour production in the eye through beta-blockade. The combination provides an additive effect for lowering intraocular pressure compared to either agent alone and is indicated for adults with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues[4][5][6][8].

Brand names
DuoTrav APSDuoTrav PQDuoTrav BAKExtravanAPO-Travoprost-Timop-Pq
Other names
0.004% travoprost/0.5% timolol
02

Targets

PTGFR (Prostaglandin F2 alpha receptor)ADRB1 (β1)

Beyond the preview

Go deeper on travoprost + timolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on travoprost + timolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call